Lucemyra (lofexidine hydrochloride), now approved by the Food and Drug Administration, may offer relief (and new hope) for patients experiencing withdrawal symptoms from opioid dependence.

This is the first non-opioid treatment for opioid withdrawal and although it may not completely prevent symptoms, it may lessen the severity (approved for use for up to 14 days). Lucemyra is not a treatment for opioid use disorder (OUD), though it can be used as part of a long-term plan for managing OUD.

In addition, many opioid addicts don’t seek treatment because they fear withdrawal symptoms or relapse easily because of them. A new medication that can ease the process may contribute to recovery rates as a whole.

Read more here on Drugs.com: https://bit.ly/2y2PH8C